ProfileGDS5678 / 1450714_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 92% 92% 92% 92% 90% 90% 91% 91% 92% 92% 93% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4868392
GSM967853U87-EV human glioblastoma xenograft - Control 27.7326992
GSM967854U87-EV human glioblastoma xenograft - Control 37.7761892
GSM967855U87-EV human glioblastoma xenograft - Control 47.7575192
GSM967856U87-EV human glioblastoma xenograft - Control 57.7665392
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.0211990
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9404290
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.423791
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4530691
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7515692
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6881392
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9495193
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.8680593
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8151293